PolyPid (Nasdaq:PYPD) announced that its management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.
Interested investors should contact their Craig-Hallum representative to arrange meetings with PolyPid.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PYPD
+1.89%
+1.89%Session close to close
In the May 20 session, PYPD gained 1.89%, reflecting a mild positive market reaction.
This announcement highlights PolyPid’s participation in the Craig-Hallum 23rd Annual Institutional I...
Analysis
This announcement highlights PolyPid’s participation in the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, reinforcing its outreach to institutional investors. It comes after several key milestones, including initiation of a rolling NDA for D-PLEX₁₀₀ and positive Phase 3 SHIELD II data showing substantial infection risk reductions. Investors may monitor progress on the NDA timeline, potential U.S. commercialization partnerships, and liquidity developments alongside future scientific and investor events.
Key Figures
Conference edition:23rd annualShare price:$4.7652-week range:$2.44–$5.12+5 more
Initiation of rolling NDA submission for D-PLEX₁₀₀ under Fast Track.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news skewed toward positive clinical and regulatory milestones, but price reactions have been mixed, with several instances where favorable updates were followed by negative moves.
Recent Company History
Over the last few months, PolyPid has focused on advancing D-PLEX₁₀₀. On Mar 31, 2026, it initiated a rolling NDA submission to the FDA, followed by additional Phase 3 SHIELD II data in April highlighting infection risk reduction and sustained local drug release. In May, the company reported Q1 2026 financials alongside NDA progress and late-stage U.S. partnership discussions. Today’s conference participation announcement fits a pattern of ongoing investor outreach layered on top of these regulatory and clinical milestones.
Key Terms
new drug application, nda, fast track, rolling review, +4 more
8 terms
new drug applicationregulatory
"has begun submitting a New Drug Application to the U.S. FDA for its lead product"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
ndaregulatory
"The NDA to the FDA was initiated March 30, 2026 under rolling review"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
fast trackregulatory
"The NDA is being filed under Fast Track designation, allowing a rolling review"
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.
rolling reviewregulatory
"The NDA is being filed under Fast Track designation, allowing a rolling review"
A rolling review is a regulatory process where health authorities examine data on a drug or vaccine as it becomes available instead of waiting for a complete file at the end. For investors, this can speed up the timeline to approval and reduce uncertainty because regulators assess progress in real time—think of reading and approving chapters of a book as they’re finished rather than waiting for the whole manuscript, which can bring forward potential market access and revenue.
breakthrough therapy designationregulatory
"and has received Breakthrough Therapy Designation from the FDA"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
phase 3medical
"announced presentation of Phase 3 SHIELD II ASEPSIS score analysis"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
pdufaregulatory
"with completion expected imminently and a PDUFA fee waiver of about $4.3 million"
PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.
pharmacokineticmedical
"will present Phase 3 SHIELD II pharmacokinetic data for D-PLEX100 at ESCMID Global 2026"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on Thursday, May 28, 2026, at the Depot Renaissance Hotel in Minneapolis, MN.
Investors interested in meeting with PolyPid should contact their Craig Hallum representative directly.
About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact: PolyPid Ltd. Ori Warshavsky 908-858-5995 IR@Polypid.com
Investor Relations Contact: Arx Investor Relations North American Equities Desk polypid@arxhq.com
FAQ
When will PolyPid (PYPD) attend the Craig-Hallum 23rd Annual Institutional Investor Conference?
PolyPid will participate in investor meetings on Thursday, May 28, 2026, at the Craig-Hallum 23rd Annual Institutional Investor Conference, held at the Depot Renaissance Hotel in Minneapolis, Minnesota, according to the company.
Where is the Craig-Hallum 23rd Annual Institutional Investor Conference with PolyPid (PYPD) being held?
The conference featuring PolyPid investor meetings will take place at the Depot Renaissance Hotel in Minneapolis, MN. According to the company, its management will be available for scheduled investor meetings there.
How can investors schedule a meeting with PolyPid (PYPD) at the Craig-Hallum conference?
Investors interested in meeting with PolyPid should contact their Craig-Hallum representative directly. According to the company, meetings will be arranged through Craig-Hallum rather than via PolyPid’s own channels.
What is PolyPid (PYPD) planning at the Craig-Hallum 23rd Annual Institutional Investor Conference?
PolyPid plans for its management team to participate in investor meetings during the Craig-Hallum 23rd Annual Institutional Investor Conference. According to the company, the focus is on direct engagement with institutional investors.
